S

Shanghai Henlius Biotech Inc
HKEX:2696

Watchlist Manager
Shanghai Henlius Biotech Inc
HKEX:2696
Watchlist
Price: 20.6 HKD -1.44% Market Closed
Market Cap: 11.2B HKD
Have any thoughts about
Shanghai Henlius Biotech Inc?
Write Note

Shanghai Henlius Biotech Inc
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Shanghai Henlius Biotech Inc
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
S
Shanghai Henlius Biotech Inc
HKEX:2696
Research & Development
-ÂĄ1.1B
CAGR 3-Years
-8%
CAGR 5-Years
-25%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Research & Development
-ÂĄ12.5B
CAGR 3-Years
-13%
CAGR 5-Years
-22%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Research & Development
-ÂĄ1.3B
CAGR 3-Years
-18%
CAGR 5-Years
-51%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Research & Development
-ÂĄ1.1B
CAGR 3-Years
-54%
CAGR 5-Years
-54%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Research & Development
-ÂĄ192.9m
CAGR 3-Years
-14%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Research & Development
-ÂĄ1B
CAGR 3-Years
-47%
CAGR 5-Years
-45%
CAGR 10-Years
N/A
No Stocks Found

Shanghai Henlius Biotech Inc
Glance View

Market Cap
11.2B HKD
Industry
Biotechnology

Shanghai Henlius Biotech, Inc. engages in the development and production of monoclonal antibody drugs. The company is headquartered in Shanghai, Shanghai and currently employs 2,234 full-time employees. The company went IPO on 2019-09-25. The Company’s main products include rituximab injection HLX01 (Hanlikang), Herceptin (trastuzumab) biosimilar HLX02, Humira (adalimumab) biosimilar HLX03 and Avastin (bevacizumab) biosimilar HLX04, as well as bio-innovative drug candidates, including HLX06 (a novel VEGFR2 inhibitor), HLX07 (an EGFR inhibitor), HLX10 (a novel PD-1 inhibitor), HLX20 (a novel PD-L1 inhibitor) and HLX22 (a novel HER2 inhibitor), among others. The firm is also engaged in the provision of related technical services. The firm operates its businesses primarily in Mainland China and the United States.

Intrinsic Value
24.35 HKD
Undervaluation 15%
Intrinsic Value
Price
S

See Also

What is Shanghai Henlius Biotech Inc's Research & Development?
Research & Development
-1.1B CNY

Based on the financial report for Dec 31, 2023, Shanghai Henlius Biotech Inc's Research & Development amounts to -1.1B CNY.

What is Shanghai Henlius Biotech Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-25%

Over the last year, the Research & Development growth was 20%. The average annual Research & Development growth rates for Shanghai Henlius Biotech Inc have been -8% over the past three years , -25% over the past five years .

Back to Top